VASCADE MVP XL VVCS Model 800-1014XL
Cardiva Medical, Inc. · Decision date Mar 27, 2026
What did the FDA approve?
FDA records P120016/S039 as a supplement to PMA P120016, with the supplement type “Panel Track”. The recorded decision is approval, dated Mar 27, 2026.
FDA approval order statement
The VASCADE MVP XL Venous Vascular Closure System (VVCS) Model 800-1014XL is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 8 14F inner diameter (17F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs. The VASCADE MVP XL Venous Vascular Closure System (VVCS) Model 800-1014XL is also indicated for enabling same day discharge in patients who have undergone catheter-based cardiac arrhythmia ablation procedures utilizing 8 14F inner diameter (17F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 27, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P120016/S039
- Regulatory pathway
- PMA supplement
- Applicant
- Cardiva Medical, Inc.
- Product code
- MGB
- Decision code
- APPR
- Decision date
- Mar 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Cardiva Medical, Inc.
- Product code
- MGB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P120016. Subsequent supplements may change the device or its indications.
FDA decision timeline
P120016 · Original PMA
VASCADE VASCULAR CLOSURE SYSTEM
P120016/S039 received
Application receipt date recorded by FDA.
P120016/S039 · FDA decision
Panel Track
P120016/S040 · Related supplement
Cardiva, VASCADE Family
P120016/S043 · Related supplement
VASCADE 5F Vascular Closure System
Timeline entries are records held by MedtechLedger for P120016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cardiva Medical, Inc. | PMA approval | Jan 31, 2013 | FDA | |
Cardiva, VASCADE FamilyP120016/S040 | Cardiva Medical, Inc. | PMA supplement | Apr 23, 2026 | FDA |
VASCADE 5F Vascular Closure SystemP120016/S043 | Cardiva Medical, Inc. | PMA supplement | Sep 10, 2026 | FDA |
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cardiva Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2900 Lakeside Dr., Suite 160, Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P120016/S039
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



